lapatinib has been researched along with su 5402 in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (su 5402) | Trials (su 5402) | Recent Studies (post-2010) (su 5402) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 191 | 0 | 77 |
| Protein | Taxonomy | lapatinib (IC50) | su 5402 (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1867 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.2675 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 2.0262 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.1867 | |
| Fibroblast growth factor receptor 1 | Mus musculus (house mouse) | 10 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.1136 | |
| Vascular endothelial growth factor receptor 1 | Mus musculus (house mouse) | 0.4 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.02 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, G; Chen, S; Chen, Y; Ding, J; Meng, L; Tong, L; Wang, J; Wang, X; Xie, Y; Yang, C | 1 |
1 other study(ies) available for lapatinib and su 5402
| Article | Year |
|---|---|
Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Furans; Humans; Inhibitory Concentration 50; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyridines; Pyrimidines | 2012 |